[
  {
    "ts": null,
    "headline": "ACHV: Second Quarter Results",
    "summary": "By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported its second quarter 2025 results and highlighted several milestones achieved since the last quarterly update. This includes forging a partnership with Omnicom for launching cytisinicline, submitting the New Drug Application (NDA), generating necessary safety exposure data for",
    "url": "https://finnhub.io/api/news?id=79bf0692ecbae92ea21fb6afbf4e5d777d1aa7be43514356329817c6b2b855ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754655240,
      "headline": "ACHV: Second Quarter Results",
      "id": 136276791,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "OMC",
      "source": "Yahoo",
      "summary": "By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported its second quarter 2025 results and highlighted several milestones achieved since the last quarterly update. This includes forging a partnership with Omnicom for launching cytisinicline, submitting the New Drug Application (NDA), generating necessary safety exposure data for",
      "url": "https://finnhub.io/api/news?id=79bf0692ecbae92ea21fb6afbf4e5d777d1aa7be43514356329817c6b2b855ea"
    }
  }
]